In a policy statement, the American Society of Clinical Oncology calls for global equity in clinical trials.
The University of Chicago Medicine Comprehensive Cancer Center has been granted a six-year, $5 million grant from NCI.
ASCO calls for global equity in cancer clinical trials
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
YOU MAY BE INTERESTED IN
The phase III frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi/Minjuvi), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP alone as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma or high-grade B-cell lymphoma, has produced positive results.
If you believe in the miraculous healing power of ivermectin, hydroxychloroquine, and the harm from vaccination for HPV and COVID-19, you’ve got a powerful friend in Sen. Ron Johnson (R-WI), chair of the Permanent Subcommittee on Investigations of the Senate Committee on Homeland Security and Governmental Affairs.
In a poignant keynote punctuated with anecdotes about grief, American Society of Clinical Oncology’s immediate past president Eric Small emphasized that the annual conference is not just about scientific discovery, but about a responsibility to translate discoveries into better outcomes for cancer patients globally.
The Centers for Medicare & Medicaid Services has released a guidance for states on how to implement Medicaid work requirements that will go into effect nationwide on Jan. 1, 2027.
OpenEvidence announced an integration of ASCO Guidelines, figures, and flowcharts into the OpenEvidence model.
